MSD is Charity Supporting Partner at the Swiss City Marathon Lucerne

Save Print

13.10.2021 13:51 Europe/Zurich

Go to all press releases

Lucerne, October 13, 2021: The Swiss City Marathon Lucerne on October 31, 2021 will take place! MSD Merck Sharp & Dohme again as sponsor of the Swiss City Marathon Lucerne and again as UNICEF charity supporting partner.

On June 8, 2021, it was announced that the Swiss City Marathon Lucerne will take place. According to the development of the epidemiological situation, the organizers have defined new procedures and worked out a protection concept with a traffic light system. The slogan of this year’s marathon is: With us you run safely!

As in the past three years, MSD is a Charity Supporting Partner of UNICEF. Every runner who completes the “UNICEF mile” integrated into the race supports the UNICEF initiative “Kangaroo Mother Care“, which aims to reduce the risk of health complications and mortality in babies weighing less than 2500 grams. Already in 2019, MSD was able to present a check of 20,000 francs to UNICEF, supporting this project for the first time. We are therefore very pleased if we can continue to support this project thanks to the help of the runners.

We have established the task of reducing maternal and neonatal mortality in our “MSD for Mothers” initiative. It is an integral part of our corporate social responsibility programs, which are aligned with the goals of the United Nations. This commitment is reflected in our mission to discover, develop and deliver innovative products and services that save and improve lives. Our social responsibility to our patients, employees, customers and the communities in which we live and work is a top priority for MSD.

About MSD in Switzerland
MSD Switzerland employs over 1000 people working in local, regional and global functions across four sites in the canton of Lucerne and one site in the canton of Zurich.
Our business activities are subdivided in the two divisions, Human Health and Animal Health.
MSD Human Health covers a broad range of biopharmaceuticals. Our areas of research and development are focusing on Oncology and Immuno-Oncology as well as Vaccines to prevent diseases for children, young people, and adults against Human Papilloma Virus (HPV), Ebola, Hepatitis, Pneumococcus, Meningococcus, Measles, Rubella, Chickenpox and Herpes Zoster. In addition, MSD is conducting research in the area of infectious diseases to find new therapeutic approaches for antibiotic resistance, HIV/Aids and Hepatitis C. Further research focuses include Immunology (auto-immune diseases) as well as Diabetes. MSD has a long-lasting legacy in contributing to major public health challenges, such as River Blindness, Ebola and SARS-CoV-2.

MSD Animal Health develops and markets products for the prevention, treatment and control of disease in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals’ well-being.

Our company has one of the largest clinical research programs worldwide. MSD Switzerland conducts 35 clinical trials per year for which the required medicines are manufactured at our research & development site in Schachen. The Schachen site operates since 2018 one of the three MSD forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products – an important contribution to patient safety.

At the newly opened Zurich site “The Circle”, our company sets the focus on research & development, data management and the commercialization of our medicines and vaccines. The Zurich hub offers a state-of-the-art work environment where our empowered, culturally diverse and inclusive workforce focuses on scientific excellence to improve people’s health.

MSD Switzerland plays an active role in its community and supports a range of local and regional initiatives as for example MSD for mothers, the health congress “Trendtage Gesundheit Luzern”, and the Swiss City Marathon Lucerne.
Since 2013, MSD Switzerland has been continuously certified as a Top Employer and is pioneering a gender-neutral parental leave program for employees.

For more information,
Follow-us on Twitter, LinkedIn and YouTube.

About MSD
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

For more information, visit and connect with us on Twitter, LinkedIn and YouTube.

Media department MSD Switzerland | Tel. 058 618 30 30
Jean-Blaise Defago (Policy & Communications Director)

© 2021 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Luzern.
All rights reserved.

CH-NON-01279 07/2021

Go to all press releases